Yahoo
Brussels - Delayed Quote EUR

Fagron NV (FAGR.BR)

23.45 +0.05 (+0.21%)
At close: October 30 at 5:35:09 PM GMT+1
Chart Range Bar
Loading chart for FAGR.BR
  • Previous Close 23.40
  • Open 23.60
  • Bid --
  • Ask --
  • Day's Range 23.45 - 23.80
  • 52 Week Range 20.00 - 25.30
  • Volume 97,298
  • Avg. Volume 100,063
  • Market Cap (intraday) 1.721B
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) 18.76
  • EPS (TTM) 1.25
  • Earnings Date --
  • Forward Dividend & Yield 0.40 (1.71%)
  • Ex-Dividend Date May 18, 2026
  • 1y Target Est 29.00

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

www.fagron.com

4,880

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

FAGR.BR
11.41%
BEL 20 (^BFX)
15.03%

1-Year Return

FAGR.BR
16.02%
BEL 20 (^BFX)
17.47%

3-Year Return

FAGR.BR
50.65%
BEL 20 (^BFX)
77.50%

5-Year Return

FAGR.BR
68.87%
BEL 20 (^BFX)
36.52%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY25
Revenue 238.7M
Earnings --
Profit Margin 0.00%

Q2

FY16

Q1

FY23

Q4

FY24

Q1

FY25

0
50M
100M
150M
200M
0.0%

Analyst Insights

View More

Analyst Price Targets

27.00
29.00 Average
23.45 Current
31.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.92%

  • Return on Assets (ttm)

    6.98%

  • Return on Equity (ttm)

    16.70%

  • Revenue (ttm)

    1.03B

  • Net Income Avi to Common (ttm)

    91.74M

  • Diluted EPS (ttm)

    1.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    131.19M

  • Total Debt/Equity (mrq)

    106.35%

  • Levered Free Cash Flow (ttm)

    67.27M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: